EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.
Identifieur interne : 000570 ( PubMed/Corpus ); précédent : 000569; suivant : 000571EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.
Auteurs : Lassina Traore ; Ouéogo Nikiema ; Abdoul Karim Ouattara ; Tegwindé Rébéca Compaore ; Serge Théophile Soubeiga ; Birama Diarra ; Dorcas Obiri-Yeboah ; Pegdwendé Abel Sorgho ; Florencia Wendkuuni Djigma ; Cyrille Bisseye ; Albert Théophane Yonli ; Jacques SimporeSource :
- Mediterranean journal of hematology and infectious diseases [ 2035-3006 ] ; 2017.
Abstract
Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There is limited data of the infection of these opportunistic viruses in Burkina Faso. The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1. The study population consisted of 238 HIV-positive patients with information on the CD4 T cell count, HIV-1 viral load and HAART. Venous blood samples collected in EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping. An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalence was noted for both subtypes (3.9% (9/238) for EBV-1 vs 4.6% (11/238) for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. EBV-2 infection was significantly higher in patients with CD4 T cell count ≥ 500 compared to those with CD4 T cell count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections was almost similar in HAART-naive and HAART-experienced patients. The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.
DOI: 10.4084/MJHID.2017.049
PubMed: 28894558
Links to Exploration step
pubmed:28894558Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.</title><author><name sortKey="Traore, Lassina" sort="Traore, Lassina" uniqKey="Traore L" first="Lassina" last="Traore">Lassina Traore</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Nikiema, Oueogo" sort="Nikiema, Oueogo" uniqKey="Nikiema O" first="Ouéogo" last="Nikiema">Ouéogo Nikiema</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Ouattara, Abdoul Karim" sort="Ouattara, Abdoul Karim" uniqKey="Ouattara A" first="Abdoul Karim" last="Ouattara">Abdoul Karim Ouattara</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Compaore, Tegwinde Rebeca" sort="Compaore, Tegwinde Rebeca" uniqKey="Compaore T" first="Tegwindé Rébéca" last="Compaore">Tegwindé Rébéca Compaore</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Soubeiga, Serge Theophile" sort="Soubeiga, Serge Theophile" uniqKey="Soubeiga S" first="Serge Théophile" last="Soubeiga">Serge Théophile Soubeiga</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Diarra, Birama" sort="Diarra, Birama" uniqKey="Diarra B" first="Birama" last="Diarra">Birama Diarra</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Obiri Yeboah, Dorcas" sort="Obiri Yeboah, Dorcas" uniqKey="Obiri Yeboah D" first="Dorcas" last="Obiri-Yeboah">Dorcas Obiri-Yeboah</name><affiliation><nlm:affiliation>Deparment of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Sorgho, Pegdwende Abel" sort="Sorgho, Pegdwende Abel" uniqKey="Sorgho P" first="Pegdwendé Abel" last="Sorgho">Pegdwendé Abel Sorgho</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Djigma, Florencia Wendkuuni" sort="Djigma, Florencia Wendkuuni" uniqKey="Djigma F" first="Florencia Wendkuuni" last="Djigma">Florencia Wendkuuni Djigma</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Bisseye, Cyrille" sort="Bisseye, Cyrille" uniqKey="Bisseye C" first="Cyrille" last="Bisseye">Cyrille Bisseye</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Yonli, Albert Theophane" sort="Yonli, Albert Theophane" uniqKey="Yonli A" first="Albert Théophane" last="Yonli">Albert Théophane Yonli</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Simpore, Jacques" sort="Simpore, Jacques" uniqKey="Simpore J" first="Jacques" last="Simpore">Jacques Simpore</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28894558</idno><idno type="pmid">28894558</idno><idno type="doi">10.4084/MJHID.2017.049</idno><idno type="wicri:Area/PubMed/Corpus">000570</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000570</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.</title><author><name sortKey="Traore, Lassina" sort="Traore, Lassina" uniqKey="Traore L" first="Lassina" last="Traore">Lassina Traore</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Nikiema, Oueogo" sort="Nikiema, Oueogo" uniqKey="Nikiema O" first="Ouéogo" last="Nikiema">Ouéogo Nikiema</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Ouattara, Abdoul Karim" sort="Ouattara, Abdoul Karim" uniqKey="Ouattara A" first="Abdoul Karim" last="Ouattara">Abdoul Karim Ouattara</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Compaore, Tegwinde Rebeca" sort="Compaore, Tegwinde Rebeca" uniqKey="Compaore T" first="Tegwindé Rébéca" last="Compaore">Tegwindé Rébéca Compaore</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Soubeiga, Serge Theophile" sort="Soubeiga, Serge Theophile" uniqKey="Soubeiga S" first="Serge Théophile" last="Soubeiga">Serge Théophile Soubeiga</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Diarra, Birama" sort="Diarra, Birama" uniqKey="Diarra B" first="Birama" last="Diarra">Birama Diarra</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Obiri Yeboah, Dorcas" sort="Obiri Yeboah, Dorcas" uniqKey="Obiri Yeboah D" first="Dorcas" last="Obiri-Yeboah">Dorcas Obiri-Yeboah</name><affiliation><nlm:affiliation>Deparment of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Sorgho, Pegdwende Abel" sort="Sorgho, Pegdwende Abel" uniqKey="Sorgho P" first="Pegdwendé Abel" last="Sorgho">Pegdwendé Abel Sorgho</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Djigma, Florencia Wendkuuni" sort="Djigma, Florencia Wendkuuni" uniqKey="Djigma F" first="Florencia Wendkuuni" last="Djigma">Florencia Wendkuuni Djigma</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Bisseye, Cyrille" sort="Bisseye, Cyrille" uniqKey="Bisseye C" first="Cyrille" last="Bisseye">Cyrille Bisseye</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Yonli, Albert Theophane" sort="Yonli, Albert Theophane" uniqKey="Yonli A" first="Albert Théophane" last="Yonli">Albert Théophane Yonli</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author><author><name sortKey="Simpore, Jacques" sort="Simpore, Jacques" uniqKey="Simpore J" first="Jacques" last="Simpore">Jacques Simpore</name><affiliation><nlm:affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</nlm:affiliation></affiliation></author></analytic><series><title level="j">Mediterranean journal of hematology and infectious diseases</title><idno type="ISSN">2035-3006</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There is limited data of the infection of these opportunistic viruses in Burkina Faso. The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1. The study population consisted of 238 HIV-positive patients with information on the CD4 T cell count, HIV-1 viral load and HAART. Venous blood samples collected in EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping. An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalence was noted for both subtypes (3.9% (9/238) for EBV-1 vs 4.6% (11/238) for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. EBV-2 infection was significantly higher in patients with CD4 T cell count ≥ 500 compared to those with CD4 T cell count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections was almost similar in HAART-naive and HAART-experienced patients. The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28894558</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>12</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2035-3006</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Mediterranean journal of hematology and infectious diseases</Title><ISOAbbreviation>Mediterr J Hematol Infect Dis</ISOAbbreviation></Journal><ArticleTitle>EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.</ArticleTitle><Pagination><MedlinePgn>e2017049</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4084/MJHID.2017.049</ELocationID><Abstract><AbstractText>Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There is limited data of the infection of these opportunistic viruses in Burkina Faso. The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1. The study population consisted of 238 HIV-positive patients with information on the CD4 T cell count, HIV-1 viral load and HAART. Venous blood samples collected in EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping. An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalence was noted for both subtypes (3.9% (9/238) for EBV-1 vs 4.6% (11/238) for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. EBV-2 infection was significantly higher in patients with CD4 T cell count ≥ 500 compared to those with CD4 T cell count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections was almost similar in HAART-naive and HAART-experienced patients. The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Traore</LastName><ForeName>Lassina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikiema</LastName><ForeName>Ouéogo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouattara</LastName><ForeName>Abdoul Karim</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compaore</LastName><ForeName>Tegwindé Rébéca</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soubeiga</LastName><ForeName>Serge Théophile</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diarra</LastName><ForeName>Birama</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obiri-Yeboah</LastName><ForeName>Dorcas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Deparment of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorgho</LastName><ForeName>Pegdwendé Abel</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djigma</LastName><ForeName>Florencia Wendkuuni</ForeName><Initials>FW</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bisseye</LastName><ForeName>Cyrille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yonli</LastName><ForeName>Albert Théophane</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpore</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomolecular Research Center Pietro Annigoni (CERBA).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABIOGENE UFR/SVT, University Ouaga I Prof. Joseph KI-ZERBO 01 BP 364 Ouagadougou, Burkina Faso.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Mediterr J Hematol Infect Dis</MedlineTA><NlmUniqueID>101530512</NlmUniqueID><ISSNLinking>2035-3006</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Blood. 1999 Jun 1;93(11):3949-55</RefSource><PMID Version="1">10339504</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Oral Patol Oral Cir Bucal. 2016 Mar 01;21(2):e157-60</RefSource><PMID Version="1">26827058</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virol J. 2010 Sep 21;7:247</RefSource><PMID Version="1">20858235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1991 Feb 7;349(6309):533-5</RefSource><PMID Version="1">1846951</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2009 Apr;9(4):246-58</RefSource><PMID Version="1">19319143</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2013 Apr;49(6):1374-403</RefSource><PMID Version="1">23485231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2013 Jan 1;207(1):80-8</RefSource><PMID Version="1">23100562</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Invest Ophthalmol Vis Sci. 1995 Sep;36(10):2040-7</RefSource><PMID Version="1">7657542</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virology. 1992 Sep;190(1):168-75</RefSource><PMID Version="1">1356286</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2004 Aug;73(4):583-8</RefSource><PMID Version="1">15221903</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1993 Apr 1;362(6419):458-62</RefSource><PMID Version="1">7681936</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2008 Aug 18;8:111</RefSource><PMID Version="1">18706107</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 1988 Feb 11;16(3):1215</RefSource><PMID Version="1">3344216</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pan Afr Med J. 2016 Aug 03;24:298</RefSource><PMID Version="1">28154653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2009 May;81(5):779-89</RefSource><PMID Version="1">19319952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1986 Oct 31;234(4776):596-601</RefSource><PMID Version="1">2876520</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2005 Aug 1;175(3):2010-7</RefSource><PMID Version="1">16034146</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Chem Lab Med. 2011 Nov;49(11):1891-8</RefSource><PMID Version="1">21756162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Ophthalmol. 1992 Sep 15;114(3):375-7</RefSource><PMID Version="1">1326231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1999 Jul;180(1):50-5</RefSource><PMID Version="1">10353860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Viruses. 2012 Dec;4(12):3420-39</RefSource><PMID Version="1">23342366</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1991 May 15;77(10):2251-8</RefSource><PMID Version="1">1674220</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2000 Aug;74(16):7610-8</RefSource><PMID Version="1">10906215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 1996 Aug;70(8):4884-94</RefSource><PMID Version="1">8763991</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2000 May;16(3):149-57</RefSource><PMID Version="1">10738135</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1990 Sep;162(3):643-8</RefSource><PMID Version="1">2167337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pathol. 2000 Oct;53(5):262-9</RefSource><PMID Version="1">11091850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 1999 Mar;57(3):278-82</RefSource><PMID Version="1">10022800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Dermatol. 2001 Mar;137(3):301-4</RefSource><PMID Version="1">11255328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1994 Jun;169(6):1342-5</RefSource><PMID Version="1">7910837</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 1997 Apr;51(4):355-63</RefSource><PMID Version="1">9093952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2001 Jul 1;98(1):146-55</RefSource><PMID Version="1">11418474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Postgrad Med. 2000 Jun;107(7):175-9, 183-4, 186</RefSource><PMID Version="1">10887454</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Microbiol. 2004 Aug;2(8):656-68</RefSource><PMID Version="1">15263900</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mediterr J Hematol Infect Dis. 2013 Sep 02;5(1):e2013053</RefSource><PMID Version="1">24106603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2003 Mar;3(3):131-40</RefSource><PMID Version="1">12614729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2001 Sep 15;33(6):829-33</RefSource><PMID Version="1">11512088</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Psychiatry. 2015 Nov 20;15:296</RefSource><PMID Version="1">26584549</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1989 Oct;8(10):3019-27</RefSource><PMID Version="1">2573513</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Mar 25;10(3):e0120710</RefSource><PMID Version="1">25807555</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 1995 Mar;45(3):288-92</RefSource><PMID Version="1">7775950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1989 Sep 30;2(8666):761-5</RefSource><PMID Version="1">2571010</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2005 Jan;18(1):217-45</RefSource><PMID Version="1">15653828</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virus Res. 2009 Aug;143(2):209-21</RefSource><PMID Version="1">19596032</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 1995 Oct;14(10):891-4</RefSource><PMID Version="1">8584318</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pan Afr Med J. 2016 Jul 12;24:223</RefSource><PMID Version="1">27800078</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Virol. 2014 May;159(5):863-70</RefSource><PMID Version="1">24193951</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 2003 Jun;77(11):6546-50</RefSource><PMID Version="1">12743312</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1989 Jan 26;337(6205):370-3</RefSource><PMID Version="1">2463490</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Gen Virol. 1992 Feb;73 ( Pt 2):455-61</RefSource><PMID Version="1">1311368</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Surg. 1958 Nov;46(197):218-23</RefSource><PMID Version="1">13628987</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD4 T cell count</Keyword><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">HHV-6</Keyword><Keyword MajorTopicYN="N">HIV-1</Keyword><Keyword MajorTopicYN="N">and treatment</Keyword><Keyword MajorTopicYN="N">subtype</Keyword><Keyword MajorTopicYN="N">viral load</Keyword></KeywordList><CoiStatement>Competing interests: The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28894558</ArticleId><ArticleId IdType="doi">10.4084/MJHID.2017.049</ArticleId><ArticleId IdType="pii">mjhid-9-1-e2017049</ArticleId><ArticleId IdType="pmc">PMC5584768</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000570 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000570 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28894558
|texte= EBV and HHV-6 Circulating Subtypes in People Living with HIV in Burkina Faso, Impact on CD4 T cell count and HIV Viral Load.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28894558" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |